retatrutide ly3437943 clinical trials Phase 3: TRIUMPH Program Results 2026 Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

This is one of the most common questions, and the answer is actually pretty simple

Epub 2023/07/29

Healthcare providers should assess: Body composition changes (not just weight) to evaluate muscle mass preservation Glycemic control in patients with diabetes, adjusting other medications as needed Thyroid function if symptoms of hypothyroidism develop (fatigue, cold intolerance) Nutritional status through clinical assessment and laboratory testing when indicated Patients experiencing excessive fatigue, cold intolerance, or other symptoms potentially indicating metabolic suppression should be evaluated promptly, though these symptoms more commonly relate to rapid weight loss itself rather than direct drug effects

38 MaJ.ShiM.ZhangX.LiuX.ChenJ.ZhangR.et al (2018)